| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
On Thursday, Sept. 30, Dr. Raymund Razonable, a Mayo Clinic infectious disease expert, answered questions about different COVID-19 treatments.
"The symptoms people experience after the vaccine are from antibody response, and that's a good thing," says Martin Herrmann, M.D., medical director of Mayo Clinic Health System in Waseca and New Prague. "That means the vaccine is working, and you're developing immune protection from the virus."
In this Mayo Clinic Q&A podcast, Dr. Poland talks more about the approval process for COVID-19 vaccine boosters, including for the Moderna and Johnson & Johnson COVID-19 vaccines. He also discusses the possibility that emergency use approval for children, down to age 5, could come before the end of October.
Pfizer announced that it submitted data of their phase 2 and phase 3 trial of their COVID-19 in children ages 5–11 to the Food and Drug Administration (FDA). A formal submission to request emergency use authorization (EUA) of the company's COVID-19 vaccine in children in this age group is expected in the coming weeks.
Throughout the COVID-19 pandemic, Mayo Clinic has remained strong and resilient, thanks to the hard work and dedication of our staff. They come to work each day to provide compassionate care to our patients.
